The Maltese Release Company
The Maltese Release Company (TMRC) is a recently established, privately owned company, located in Malta. TMRC provides access to testing and release services in any dosage form and offers you analytical method development and validation.
The Maltese Release Company (TMRC) is a recently established, privately owned company, located in Malta in the pharmaceutical industrial park of Hal Far.
TMRC was born from a Joint Venture between COMBINO PHARM and ALFRED E. TIEFENBACHER, to offer a vast range of services to pharmaceutical companies.
The strategic location of TMRC permits us to perform EU-GMP testing and release of pharmaceutical products even before the end of patent term, allowing our clients the great opportunity to start selling products in the EU market from day one, a huge advantage when compared to other competitors.
The company counts on a diverse team of highly skilled and experienced individuals both in quality control analysis as well as quality assurance.
For more information please contact us info@themalteserelease.com.mt or visit www.themalteserelease.com.mt
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.
